Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
These S&P 500 technology titans are buying back tens of billions of dollars' worth of their own stock this year. → Read More
These tips can help you navigate a tumbling tape. → Read More
You might want to add these retailers to your portfolio's wish list while you're hunting for gifts for family and friends this weekend. → Read More
You could miss out on market-beating returns if you don't have these top stocks in your portfolio. → Read More
Retirees are already spending the increase, and even worse, their costs in 2019 may increase by even more than they're getting. → Read More
These large-cap stocks offer solid dividend income and an opportunity for upside in share prices. → Read More
Expenses in retirement are increasing faster than Social Security income, and that's straining seniors' budgets. → Read More
Value investing is alive and well. → Read More
Here's how much money the average married couple is receiving in Social Security benefits this year. → Read More
There are thousands of publicly traded stocks, but I settled on adding these three to my portfolio this month. → Read More
It could be a great time to add this energy stock to your portfolio. → Read More
The stocks that Warren Buffett is selling may surprise you. → Read More
If you're not sure what stocks to own in 2018, consider starting with these three ideas. → Read More
Rite Aid recently updated investors on the progress it's making toward improving its profitability. → Read More
The eclectic list of the S&P 500's best-performing stocks may surprise you. → Read More
Including this big-cap biopharma in healthcare portfolios next month could be a savvy move. → Read More
Berkshire Hathaway's portfolio doesn't change very often, but when it does, investors ought to know about it, especially if they own stocks Warren Buffett is selling. → Read More
A strong economy and low unemployment make it a good time to consider adding bank stocks to your portfolio. → Read More
If Spark Therapeutics' game-changing new treatment Luxturna gets FDA approval in January, it may launch with an eye-popping price tag. → Read More
Other insurers may be retreating from the Affordable Care Act marketplaces, but this insurer's not only making money on the exchanges -- it's also planning to sell plans in more states next year. → Read More